Summary
Regeneron Pharmaceuticals, Inc. reported strong revenue growth in the first quarter of 2015, driven primarily by a significant increase in EYLEA net product sales, which rose to $541.1 million from $359.0 million in the prior year's comparable quarter. This 50% year-over-year increase highlights the continued market adoption and success of EYLEA for its approved ophthalmic indications. Collaboration revenue also saw a healthy increase, particularly from the Sanofi partnership, bolstered by the amended ZALTRAP agreement and increased reimbursements for antibody development, signaling robust progress in their joint development programs for key pipeline assets like Praluent and Dupilumab. The company's net income grew to $76.0 million, or $0.66 per diluted share, compared to $68.3 million, or $0.61 per diluted share, in the first quarter of 2014. While research and development expenses increased, reflecting continued investment in their extensive pipeline, the company also benefited from strong collaboration revenue and managed its selling, general, and administrative expenses effectively. Regeneron ended the quarter with a solid cash position, although cash used in operating activities was negative, largely due to an increase in accounts receivable. The company also secured a new $750 million revolving credit facility, enhancing its financial flexibility.
Financial Highlights
46 data points| Revenue | $869.61M |
| Cost of Revenue | $42.57M |
| Gross Profit | $827.04M |
| R&D Expenses | $343.11M |
| SG&A Expenses | $158.99M |
| Operating Expenses | $586.06M |
| Operating Income | $283.55M |
| Interest Expense | $6.17M |
| Net Income | $76.02M |
| EPS (Basic) | $0.74 |
| EPS (Diluted) | $0.66 |
| Shares Outstanding (Basic) | 102.23M |
| Shares Outstanding (Diluted) | 114.52M |
Key Highlights
- 1EYLEA net product sales in the U.S. increased by 50% to $541.1 million in Q1 2015 compared to $359.0 million in Q1 2014.
- 2Total revenues grew to $869.6 million, a 39% increase from $625.7 million in the prior year's quarter, driven by product sales and collaboration revenue.
- 3Net income rose to $76.0 million ($0.66/share) in Q1 2015 from $68.3 million ($0.61/share) in Q1 2014.
- 4Sanofi collaboration revenue increased to $173.4 million from $130.5 million, primarily due to the amended ZALTRAP agreement and increased R&D expense reimbursements.
- 5Research and development expenses increased by 19% to $343.1 million, reflecting continued investment in pipeline development.
- 6The company entered into a new $750 million senior unsecured revolving credit facility in March 2015.
- 7Regeneron settled conversion obligations for $16.7 million of its convertible senior notes and issued 146,253 shares of common stock.